Shares of Dermira Inc (NASDAQ:DERM) have been assigned a consensus recommendation of “Hold” from the eleven research firms that are covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $41.00.

A number of equities analysts have recently weighed in on the company. Mizuho reissued a “buy” rating and issued a $43.00 price target (up from $40.00) on shares of Dermira in a report on Thursday, September 7th. Leerink Swann reissued an “outperform” rating and issued a $41.00 price target (down from $47.00) on shares of Dermira in a report on Tuesday, November 7th. Guggenheim assumed coverage on Dermira in a report on Tuesday, December 5th. They issued a “buy” rating for the company. Needham & Company LLC reissued a “buy” rating and issued a $43.00 price target (down from $46.00) on shares of Dermira in a report on Tuesday, November 7th. Finally, BidaskClub raised Dermira from a “sell” rating to a “hold” rating in a report on Saturday, December 2nd.

Dermira (NASDAQ:DERM) traded up $0.43 on Thursday, reaching $27.06. The company’s stock had a trading volume of 840,560 shares, compared to its average volume of 581,408. Dermira has a one year low of $21.35 and a one year high of $38.75. The company has a current ratio of 4.68, a quick ratio of 4.68 and a debt-to-equity ratio of 1.40.

In related news, CEO Thomas G. Wiggans sold 5,000 shares of the company’s stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $27.51, for a total value of $137,550.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Eugene A. Bauer sold 7,500 shares of the company’s stock in a transaction on Wednesday, October 11th. The shares were sold at an average price of $30.04, for a total value of $225,300.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 33,800 shares of company stock valued at $946,975. Insiders own 13.30% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Platinum Investment Management Ltd. increased its stake in Dermira by 28.8% in the second quarter. Platinum Investment Management Ltd. now owns 57,700 shares of the biopharmaceutical company’s stock valued at $1,681,000 after purchasing an additional 12,900 shares during the last quarter. Jennison Associates LLC increased its stake in Dermira by 0.3% in the third quarter. Jennison Associates LLC now owns 2,640,740 shares of the biopharmaceutical company’s stock valued at $71,300,000 after purchasing an additional 7,746 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Dermira in the first quarter valued at $1,023,000. Schwab Charles Investment Management Inc. increased its stake in Dermira by 24.1% in the second quarter. Schwab Charles Investment Management Inc. now owns 140,495 shares of the biopharmaceutical company’s stock valued at $4,095,000 after purchasing an additional 27,259 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in Dermira by 9.8% in the second quarter. Vanguard Group Inc. now owns 1,397,857 shares of the biopharmaceutical company’s stock valued at $40,735,000 after purchasing an additional 125,157 shares during the last quarter. Hedge funds and other institutional investors own 99.54% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was first reported by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.watchlistnews.com/analysts-set-dermira-inc-derm-target-price-at-43-20/1770229.html.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.